181 8.1. Professionnels de, Congres internationaux, p.183 ,
Definitions and diagnosis of pulmonary hypertension, J Am Coll Cardiol, vol.62, pp.42-50, 2013. ,
Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review, European Respiratory Journal, vol.34, issue.4, pp.888-894, 2009. ,
DOI : 10.1183/09031936.00145608
Clinical classification of pulmonary hypertension, Journal of the American College of Cardiology, vol.43, issue.12, pp.5-12, 2004. ,
DOI : 10.1016/j.jacc.2004.02.037
Pulmonary Arterial Hypertension, New England Journal of Medicine, vol.351, issue.16, pp.1655-1665, 2004. ,
DOI : 10.1056/NEJMra035488
Updated clinical classification of pulmonary hypertension, J Am Coll Cardiol, 2009. ,
Prognosis of Pulmonary Arterial Hypertension*, Chest, vol.126, issue.1, pp.78-92, 2004. ,
DOI : 10.1378/chest.126.1_suppl.78S
Idiopathic pulmonary arterial hypertension: current state of play and new treatment modalities, International Journal of Cardiology, vol.97, pp.7-10, 2004. ,
DOI : 10.1016/j.ijcard.2004.08.003
HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study., American Journal of Respiratory and Critical Care Medicine, vol.155, issue.3, pp.990-995, 1997. ,
DOI : 10.1164/ajrccm.155.3.9117037
Guidelines on diagnosis and treatment of pulmonary arterial hypertension, Eur Heart J, vol.25, pp.2243-2278, 2004. ,
Pulmonary Arterial Hypertension in France, American Journal of Respiratory and Critical Care Medicine, vol.173, issue.9, pp.1023-1030, 2006. ,
DOI : 10.1164/rccm.200510-1668OC
Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension, New England Journal of Medicine, vol.335, issue.9, pp.609-616, 1996. ,
DOI : 10.1056/NEJM199608293350901
Primary Pulmonary Hypertension, Annals of Internal Medicine, vol.107, issue.2, pp.216-223, 1987. ,
DOI : 10.7326/0003-4819-107-2-216
Primary Pulmonary Hypertension, New England Journal of Medicine, vol.336, issue.2, pp.111-117, 1997. ,
DOI : 10.1056/NEJM199701093360207
Mutation in the Gene for Bone Morphogenetic Protein Receptor II as a Cause of Primary Pulmonary Hypertension in a Large Kindred, New England Journal of Medicine, vol.345, issue.5, pp.319-324, 2001. ,
DOI : 10.1056/NEJM200108023450502
Recent Studies in Primary Pulmonary Hypertension Including Pharmacodynamic Observations on Pulmonary Vascular Resistance, Bull N Y Acad Med, vol.30, pp.195-207, 1954. ,
Familial Primary Pulmonary Hypertension (Gene PPH1) Is Caused by Mutations in the Bone Morphogenetic Protein Receptor???II Gene, The American Journal of Human Genetics, vol.67, issue.3, pp.737-781, 2000. ,
DOI : 10.1086/303059
Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension., American Journal of Respiratory and Critical Care Medicine, vol.152, issue.1, pp.93-100, 1995. ,
DOI : 10.1164/ajrccm.152.1.7599869
Genes and Pulmonary Arterial Hypertension, Respiration, vol.102, issue.2, pp.123-155, 2007. ,
DOI : 10.1161/01.CIR.102.16.2005
Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension., American Journal of Respiratory and Critical Care Medicine, vol.152, issue.1, pp.93-97, 1995. ,
DOI : 10.1164/ajrccm.152.1.7599869
Mutations in the TGF-beta type 1 receptor, ALK1, in combined primary pulmonary hypertension and hereditary haemorrhagic telangiectasia, implies pathway specificity, The Journal of Heart and Lung Transplantation, vol.20, issue.2, p.175, 2001. ,
DOI : 10.1016/S1053-2498(00)00352-1
Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension, Journal of Clinical Investigation, vol.108, issue.8, pp.1141-1150, 2001. ,
DOI : 10.1172/JCI200112805
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC209526/pdf
Genetics of pulmonary hypertension: from bench to bedside, European Respiratory Journal, vol.20, issue.3, pp.741-749, 2002. ,
DOI : 10.1183/09031936.02.02702002
Pulmonary Arterial Hypertension, New England Journal of Medicine, vol.351, issue.16, pp.1655-1665, 2004. ,
DOI : 10.1056/NEJMra035488
An Imbalance between the Excretion of Thromboxane and Prostacyclin Metabolites in Pulmonary Hypertension, New England Journal of Medicine, vol.327, issue.2, pp.70-75, 1992. ,
DOI : 10.1056/NEJM199207093270202
Reduced Expression of Endothelial Nitric Oxide Synthase in the Lungs of Patients with Pulmonary Hypertension, New England Journal of Medicine, vol.333, issue.4, pp.214-221, 1995. ,
DOI : 10.1056/NEJM199507273330403
Expression of Endothelin-1 in the Lungs of Patients with Pulmonary Hypertension, New England Journal of Medicine, vol.328, issue.24, pp.1732-1739, 1993. ,
DOI : 10.1056/NEJM199306173282402
Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future?, Journal of the American College of Cardiology, vol.37, issue.6, pp.1493-1505, 2001. ,
DOI : 10.1016/S0735-1097(01)01210-4
Increased plasma serotonin in primary pulmonary hypertension, The American Journal of Medicine, vol.99, issue.3, pp.249-254, 1995. ,
DOI : 10.1016/S0002-9343(99)80156-9
Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension, Journal of Clinical Investigation, vol.111, issue.9, pp.1339-1346, 2003. ,
DOI : 10.1172/JCI17500
Attenuated K+ channel gene transcription in primary pulmonary hypertension, Lancet, vol.351, pp.726-727, 1998. ,
Inhibition of K(V) and K(Ca) channels antagonizes NO-induced relaxation in pulmonary artery, Am J Physiol, vol.272, pp.904-912, 1997. ,
Increased plasma levels of adrenomedullin in patients with pulmonary hypertension, Clinical Science, vol.96, issue.1, pp.33-39, 1999. ,
DOI : 10.1042/cs0960033
Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis, The Journal of Pathology, vol.88, issue.3, pp.367-374, 2001. ,
DOI : 10.1161/01.RES.88.1.e2
Guidelines on diagnosis and treatment of pulmonary arterial hypertension, Eur Heart J, vol.25, pp.2243-2278, 2004. ,
Pulmonary hypertension, Continuing Education in Anaesthesia, Critical Care & Pain, vol.6, issue.1, pp.17-22, 2006. ,
DOI : 10.1093/bjaceaccp/mki061
Electrocardiography to Define Clinical Status in Primary Pulmonary Hypertension and Pulmonary Arterial Hypertension Secondary to Collagen Vascular Disease, Chest, vol.122, issue.2, pp.524-527, 2002. ,
DOI : 10.1378/chest.122.2.524
Evaluation of pulmonary arterial hypertension, Current Opinion in Cardiology, vol.19, issue.6, pp.575-581, 2004. ,
DOI : 10.1097/01.hco.0000142066.14966.85
Diagnosis and differential assessment of pulmonary arterial hypertension, Journal of the American College of Cardiology, vol.43, issue.12, pp.405-452, 2004. ,
DOI : 10.1016/j.jacc.2004.02.032
Making a diagnosis in PAH, European Respiratory Review, vol.16, issue.102, pp.8-12, 2007. ,
DOI : 10.1183/09059180.00010203
URL : http://err.ersjournals.com/content/errev/16/102/8.full.pdf
Assessment of Pulmonary Vascular Resistance by Doppler Echocardiography in Patients With Pulmonary Arterial Hypertension, The Journal of Heart and Lung Transplantation, vol.26, issue.9, pp.927-934, 2007. ,
DOI : 10.1016/j.healun.2007.06.008
Lung function testing in patients with pulmonary arterial hypertension, Arch Bronconeumol, vol.41, pp.380-384, 2005. ,
ABC of oxygen: Assessing and interpreting arterial blood gases and acid-base balance, BMJ, vol.317, issue.7167, p.1213, 1998. ,
DOI : 10.1136/bmj.317.7167.1213
Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension, European Respiratory Journal, vol.29, issue.5, p.134506, 2007. ,
DOI : 10.1183/09031936.00134506
Ventilation-Perfusion lung scanning in the evaluation of pulmonary hypertension, J Nuclear Med, vol.35, pp.793-796, 1994. ,
The six minute walking test, Respir Care, vol.48, pp.783-785, 2003. ,
Clinical Correlates and Prognostic Significance of Six-minute Walk Test in Patients with Primary Pulmonary Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.161, issue.2, pp.487-492, 2000. ,
DOI : 10.1164/ajrccm.161.2.9906015
End points and clinical trial designs in pulmonary arterial hypertension. Clinical and regulatory perspective, J Am Coll Cardiol, vol.43, pp.485-555, 2004. ,
Primary Pulmonary Hypertension, Annals of Internal Medicine, vol.107, issue.2, pp.216-223, 1987. ,
DOI : 10.7326/0003-4819-107-2-216
Central venous pressure and pulmonary capillary wedge pressure monitoring, Indian J Anaesth, vol.46, pp.298-303, 2002. ,
Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension, Circulation, vol.1, issue.1, pp.3105-3111, 2005. ,
DOI : 10.1161/circulationaha.104.488486
URL : http://circ.ahajournals.org/content/circulationaha/111/23/3105.full.pdf
Prognosis of Pulmonary Arterial Hypertension*, Chest, vol.126, issue.1, pp.78-92, 2004. ,
DOI : 10.1378/chest.126.1_suppl.78S
Medical therapy for pulmonary arterial hypertension, Chest, vol.126, issue.1, pp.355-62, 2004. ,
Primary Pulmonary Hypertension, Chest, vol.105, issue.2, pp.33-36, 1994. ,
DOI : 10.1378/chest.105.2_Supplement.33S
Survival in Patients with Primary Pulmonary Hypertension, Annals of Internal Medicine, vol.115, issue.5, pp.343-349, 1991. ,
DOI : 10.7326/0003-4819-115-5-343
Clinical Correlates and Prognostic Significance of Six-minute Walk Test in Patients with Primary Pulmonary Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.161, issue.2, pp.487-492, 2000. ,
DOI : 10.1164/ajrccm.161.2.9906015
Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension, European Respiratory Journal, vol.17, issue.4, pp.647-652, 2001. ,
DOI : 10.1183/09031936.01.17406470
Assessment of Survival in Patients With Primary Pulmonary Hypertension: Importance of Cardiopulmonary Exercise Testing, Circulation, vol.106, issue.3, pp.319-324, 2002. ,
DOI : 10.1161/01.CIR.0000022687.18568.2A
Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension, Circulation, vol.111, issue.23, pp.3105-3111, 2005. ,
DOI : 10.1161/CIRCULATIONAHA.104.488486
URL : http://circ.ahajournals.org/content/circulationaha/111/23/3105.full.pdf
Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension, Journal of the American College of Cardiology, vol.39, issue.7, pp.1214-1219, 2002. ,
DOI : 10.1016/S0735-1097(02)01744-8
Value of a Doppler-Derived Index Combining Systolic and Diastolic Time Intervals in Predicting Outcome in Primary Pulmonary Hypertension, The American Journal of Cardiology, vol.81, issue.9, pp.1157-1161, 1998. ,
DOI : 10.1016/S0002-9149(98)00140-4
Tricuspid Annular Displacement Predicts Survival in Pulmonary Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.174, issue.9, pp.1034-1041, 2006. ,
DOI : 10.1164/rccm.200604-547OC
URL : http://intl-ajrccm.atsjournals.org/content/174/9/1034.full.pdf
Plasma Brain Natriuretic Peptide as a Prognostic Indicator in Patients With Primary Pulmonary Hypertension, Circulation, vol.102, issue.8, pp.865-870, 2000. ,
DOI : 10.1161/01.CIR.102.8.865
NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension, Respiratory Medicine, vol.101, issue.1, pp.69-75, 2007. ,
DOI : 10.1016/j.rmed.2006.04.014
Big Endothelin-1 and Endothelin-1 Plasma Levels Are Correlated With the Severity of Primary Pulmonary Hypertension, Chest, vol.120, issue.5, pp.1562-1569, 2001. ,
DOI : 10.1378/chest.120.5.1562
Serum Uric Acid Levels Correlate with the Severity and the Mortality of Primary Pulmonary Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.160, issue.2, pp.487-492, 1999. ,
DOI : 10.1164/ajrccm.160.2.9812078
Detectable Serum Cardiac Troponin T as a Marker of Poor Prognosis Among Patients With Chronic Precapillary Pulmonary Hypertension, Circulation, vol.108, issue.7, pp.844-848, 2003. ,
DOI : 10.1161/01.CIR.0000084544.54513.E2
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension, Journal of the American College of Cardiology, vol.40, issue.4, pp.780-788, 2002. ,
DOI : 10.1016/S0735-1097(02)02012-0
URL : https://doi.org/10.1016/s0735-1097(02)02012-0
Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy, Circulation, vol.106, issue.12, pp.1477-1482, 2002. ,
DOI : 10.1161/01.CIR.0000029100.82385.58
Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension, European Heart Journal, vol.27, issue.5, pp.589-595, 2006. ,
DOI : 10.1093/eurheartj/ehi728
Clinical Challenges in Pulmonary Hypertension, Chest, vol.128, issue.6, pp.622-628, 2005. ,
DOI : 10.1378/chest.128.6_suppl.622S
Bosentan delays time to clinical worsening (TTCW) and improves haemodynamics in WHO Class II pulmonary arterial hypertension (PAH) patients: EARLY study results, 2007. ,
Treatment of Pulmonary Arterial Hypertension, New England Journal of Medicine, vol.351, issue.14, pp.1425-1436, 2004. ,
DOI : 10.1056/NEJMra040291
URL : https://hal.archives-ouvertes.fr/hal-01455600
Survival in Patients with Primary Pulmonary Hypertension, Annals of Internal Medicine, vol.115, issue.5, pp.343-349, 1991. ,
DOI : 10.7326/0003-4819-115-5-343
End points and clinical trial designs in pulmonary arterial hypertension. Clinical and regulatory perspectives, JAm Coll Cardiol, vol.43, pp.485-555, 2004. ,
High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy, Circulation, vol.76, issue.1, pp.135-141, 1987. ,
DOI : 10.1161/01.CIR.76.1.135
The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary Hypertension, New England Journal of Medicine, vol.327, issue.2, pp.76-81, 1992. ,
DOI : 10.1056/NEJM199207093270203
Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension, European Respiratory Journal, vol.12, issue.2, pp.265-270, 1998. ,
DOI : 10.1183/09031936.98.12020265
Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension, Circulation, vol.111, issue.23, pp.3105-3111, 2005. ,
DOI : 10.1161/CIRCULATIONAHA.104.488486
URL : http://circ.ahajournals.org/content/circulationaha/111/23/3105.full.pdf
The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary Hypertension, New England Journal of Medicine, vol.327, issue.2, pp.76-81, 1992. ,
DOI : 10.1056/NEJM199207093270203
Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension, Circulation, vol.111, issue.23, pp.3105-3111, 2005. ,
DOI : 10.1161/CIRCULATIONAHA.104.488486
URL : http://circ.ahajournals.org/content/circulationaha/111/23/3105.full.pdf
MEDICAL THERAPY OF PULMONARY HYPERTENSION, Clinics in Chest Medicine, vol.22, issue.3, pp.517-527, 2001. ,
DOI : 10.1016/S0272-5231(05)70288-4
Diagnosis and treatment of pulmonary arterial hypertension, Cardiology Clinics, vol.22, issue.3, pp.441-452, 2004. ,
DOI : 10.1016/j.ccl.2004.04.004
Primary pulmonary hypertension: natural history and the importance of thrombosis, Circulation, vol.70, issue.4, pp.580-587, 1984. ,
DOI : 10.1161/01.CIR.70.4.580
Endothelin receptor antagonists in pulmonary arterial hypertension, Journal of the American College of Cardiology, vol.43, issue.12, pp.62-67, 2004. ,
DOI : 10.1016/j.jacc.2004.02.042
Bosentan Therapy for Pulmonary Arterial Hypertension, New England Journal of Medicine, vol.346, issue.12, pp.896-903, 2002. ,
DOI : 10.1056/NEJMoa012212
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study, The Lancet, vol.358, issue.9288, pp.1119-1123, 2001. ,
DOI : 10.1016/S0140-6736(01)06250-X
Bosentan Therapy for Pulmonary Arterial Hypertension, New England Journal of Medicine, vol.346, issue.12, pp.896-903, 2002. ,
DOI : 10.1056/NEJMoa012212
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2, European Respiratory Journal, vol.24, issue.3, pp.353-359, 2004. ,
DOI : 10.1183/09031936.04.00028404
Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial, The Lancet, vol.371, issue.9630, pp.2093-2100, 2008. ,
DOI : 10.1016/S0140-6736(08)60919-8
Bosentan Therapy in Patients With Eisenmenger Syndrome: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study, Circulation, vol.114, issue.1, pp.48-54, 2006. ,
DOI : 10.1161/CIRCULATIONAHA.106.630715
Treatment of Pulmonary Arterial Hypertension With the Selective Endothelin-A Receptor Antagonist Sitaxsentan, Journal of the American College of Cardiology, vol.47, issue.10, pp.2049-2056, 2006. ,
DOI : 10.1016/j.jacc.2006.01.057
Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension, New England Journal of Medicine, vol.369, issue.9, pp.809-818, 2013. ,
DOI : 10.1056/NEJMoa1213917
Tadalafil Therapy for Pulmonary Arterial Hypertension, Circulation, vol.119, issue.22, pp.2894-2903, 2009. ,
DOI : 10.1161/CIRCULATIONAHA.108.839274
URL : http://circ.ahajournals.org/content/circulationaha/119/22/2894.full.pdf
Vardenafil in Pulmonary Arterial Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.183, issue.12, pp.1723-1729, 2011. ,
DOI : 10.1164/rccm.201101-0093OC
Reduced Expression of Endothelial Nitric Oxide Synthase in the Lungs of Patients with Pulmonary Hypertension, New England Journal of Medicine, vol.333, issue.4, pp.214-221, 1995. ,
DOI : 10.1056/NEJM199507273330403
Riociguat for the Treatment of Pulmonary Arterial Hypertension, New England Journal of Medicine, vol.369, issue.4, pp.330-340, 2013. ,
DOI : 10.1056/NEJMoa1209655
PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension, European Respiratory Journal, vol.45, issue.5, pp.1314-1322, 2015. ,
DOI : 10.1183/09031936.00105914
Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial, Journal of the American College of Cardiology, vol.39, issue.9, pp.1496-502, 2002. ,
DOI : 10.1016/S0735-1097(02)01786-2
Beraprost therapy for pulmonary arterial hypertension, Journal of the American College of Cardiology, vol.41, issue.12, pp.2119-2144, 2003. ,
DOI : 10.1016/S0735-1097(03)00463-7
URL : https://doi.org/10.1016/s0735-1097(03)00463-7
Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol), Annals of Internal Medicine, vol.112, issue.7, pp.485-491, 1990. ,
DOI : 10.7326/0003-4819-112-7-485
A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension, New England Journal of Medicine, vol.334, issue.5, pp.296-302, 1996. ,
DOI : 10.1056/NEJM199602013340504
Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease, Annals of Internal Medicine, vol.132, issue.6, pp.425-434, 2000. ,
DOI : 10.7326/0003-4819-132-6-200003210-00002
Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension, International Journal of Clinical Practice, vol.60, issue.Suppl., pp.5-9, 2008. ,
DOI : 10.1111/j.1742-1241.2008.01811.x
EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension, American Heart Journal, vol.167, issue.2, pp.210-217, 2014. ,
DOI : 10.1016/j.ahj.2013.08.007
Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.165, issue.6, pp.800-804, 2002. ,
DOI : 10.1164/ajrccm.165.6.2106079
Inhaled Iloprost for Severe Pulmonary Hypertension, New England Journal of Medicine, vol.347, issue.5, pp.322-329, 2002. ,
DOI : 10.1056/NEJMoa020204
Inhaled Iloprost for Severe Pulmonary Hypertension, New England Journal of Medicine, vol.347, issue.5, pp.322-329, 2002. ,
DOI : 10.1056/NEJMoa020204
Randomized Study of Adding Inhaled Iloprost to Existing Bosentan in Pulmonary Arterial Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.174, issue.11, pp.1257-1263, 2006. ,
DOI : 10.1164/rccm.200603-358OC
Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension, European Respiratory Journal, vol.28, issue.4, pp.691-694, 2006. ,
DOI : 10.1183/09031936.06.00057906
Long term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension, Heart, vol.80, issue.2, pp.151-155, 1998. ,
DOI : 10.1136/hrt.80.2.151
New Treatment Strategies for Pulmonary Arterial Hypertension, Journal of the American College of Cardiology, vol.62, issue.12, pp.1101-1102, 2013. ,
DOI : 10.1016/j.jacc.2013.06.032
Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension, Journal of the American College of Cardiology, vol.62, issue.12, pp.1092-1100, 2013. ,
DOI : 10.1016/j.jacc.2013.05.075
URL : https://doi.org/10.1016/j.jacc.2013.05.075
Goal-oriented treatment and combination therapy for pulmonary arterial hypertension, European Respiratory Journal, vol.26, issue.5, pp.858-863, 2005. ,
DOI : 10.1183/09031936.05.00075305
URL : http://erj.ersjournals.com/content/erj/26/5/858.full.pdf
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension, New England Journal of Medicine, vol.373, issue.9, pp.834-844, 2015. ,
DOI : 10.1056/NEJMoa1413687
Blade Balloon Atrial Septostomy in Patients With Severe Primary Pulmonary Hypertension, Circulation, vol.91, issue.7, pp.2028-2035, 1995. ,
DOI : 10.1161/01.CIR.91.7.2028
Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension, The American Journal of Cardiology, vol.84, issue.6, pp.682-686, 1999. ,
DOI : 10.1016/S0002-9149(99)00416-6
Introduction, Chest, vol.126, issue.1, pp.7-10, 2004. ,
DOI : 10.1378/chest.126.1_suppl.7S
URL : https://hal.archives-ouvertes.fr/hal-00989924
ATRIAL SEPTOSTOMY FOR PULMONARY HYPERTENSION, Clinics in Chest Medicine, vol.22, issue.3, pp.547-560, 2001. ,
DOI : 10.1016/S0272-5231(05)70291-4
Factors that influence the outcome of primary pulmonary hypertension., Heart, vol.55, issue.5, pp.449-458, 1986. ,
DOI : 10.1136/hrt.55.5.449
Single Lung Transplantation for Primary Pulmonary Hypertension, Chest, vol.98, issue.5, pp.1107-1115, 1990. ,
DOI : 10.1378/chest.98.5.1107
URL : http://publications.chestnet.org//pdfAccess.ashx?url=%2Fdata%2FJournals%2FCHEST%2F21620%2F1107.pdf
Lung and heart-lung transplant practice patterns in pulmonary hypertension centers, The Journal of Heart and Lung Transplantation, vol.20, issue.12, pp.1297-1304, 2001. ,
DOI : 10.1016/S1053-2498(01)00348-5
Lung transplantation for pulmonary vascular disease, The Annals of Thoracic Surgery, vol.73, issue.1, pp.209-217, 2002. ,
DOI : 10.1016/S0003-4975(01)03082-X
Heart-Lung Transplantation, New England Journal of Medicine, vol.306, issue.10, pp.557-564, 1982. ,
DOI : 10.1056/NEJM198203113061001
The registry of the international society for heart and lung transplantation: eighteenth official report???2001, The Journal of Heart and Lung Transplantation, vol.20, issue.8, pp.805-815, 2001. ,
DOI : 10.1016/S1053-2498(01)00323-0
Pulmonary Arterial Hypertension, Proceedings of the American Thoracic Society, vol.3, issue.1, pp.111-115, 2006. ,
DOI : 10.1513/pats.200510-112JH
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension, Journal of the American College of Cardiology, vol.40, issue.4, pp.780-788, 2002. ,
DOI : 10.1016/S0735-1097(02)02012-0
URL : https://doi.org/10.1016/s0735-1097(02)02012-0
The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension, European Respiratory Journal, vol.39, issue.3, pp.589-596, 2012. ,
DOI : 10.1183/09031936.00092311
Functional Class Improvement and 3-Year Survival Outcomes in Patients With Pulmonary Arterial Hypertension in the REVEAL Registry, Chest, vol.144, issue.1, pp.160-168, 2013. ,
DOI : 10.1378/chest.12-2417
Accuracy of Right Ventricular Volumes and Function Determined by Three-Dimensional Echocardiography in Comparison with Magnetic Resonance Imaging: A??Meta-Analysis Study, Journal of the American Society of Echocardiography, vol.23, issue.9, pp.943-953, 2010. ,
DOI : 10.1016/j.echo.2010.06.029
Assessment and Prognostic Relevance of Right Ventricular Contractile Reserve in Patients With Severe Pulmonary Hypertension, Circulation, vol.128, issue.18, pp.2005-2015, 2013. ,
DOI : 10.1161/CIRCULATIONAHA.113.001573
Do Changes of 6-Minute Walk Distance Predict Clinical Events in Patients With Pulmonary Arterial Hypertension?, Journal of the American College of Cardiology, vol.60, issue.13, pp.1192-1201, 2012. ,
DOI : 10.1016/j.jacc.2012.01.083
Validation of 6-Minute Walk Distance as a Surrogate End Point in Pulmonary Arterial Hypertension Trials, Circulation, vol.126, issue.3, pp.349-356, 2012. ,
DOI : 10.1161/CIRCULATIONAHA.112.105890
Baseline and Follow-up 6-Min Walk Distance and Brain Natriuretic Peptide Predict 2-Year Mortality in Pulmonary Arterial Hypertension, Chest, vol.143, issue.2, pp.315-323, 2013. ,
DOI : 10.1378/chest.12-0270
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694187/pdf
Incremental prognostic value of cardiopulmonary exercise testing and resting haemodynamics in pulmonary arterial hypertension, International Journal of Cardiology, vol.167, issue.4, pp.1193-1198, 2013. ,
DOI : 10.1016/j.ijcard.2012.03.135
Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension, FASEB J, vol.19, pp.1175-1177, 2005. ,
Asymmetrical Dimethylarginine in Idiopathic Pulmonary Arterial Hypertension, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.25, issue.7, pp.1414-1418, 2005. ,
DOI : 10.1161/01.ATV.0000168414.06853.f0
URL : http://atvb.ahajournals.org/content/atvbaha/25/7/1414.full.pdf
Cardiovascular Effects of Systemic Nitric Oxide Synthase Inhibition With Asymmetrical Dimethylarginine in Humans, Circulation, vol.109, issue.2, pp.172-177, 2004. ,
DOI : 10.1161/01.CIR.0000105764.22626.B1
von Willebrand Factor Independently Predicts Long-term Survival in Patients With Pulmonary Arterial Hypertension, Chest, vol.128, issue.4, pp.2355-2362, 2005. ,
DOI : 10.1378/chest.128.4.2355
Circulating angiopoietins in idiopathic pulmonary arterial hypertension, European Heart Journal, vol.31, issue.18, pp.2291-2300, 2010. ,
DOI : 10.1093/eurheartj/ehq226
Big Endothelin-1 and Endothelin-1 Plasma Levels Are Correlated With the Severity of Primary Pulmonary Hypertension, Chest, vol.120, issue.5, pp.1562-1569, 2001. ,
DOI : 10.1378/chest.120.5.1562
C-Reactive Protein, Journal of the American College of Cardiology, vol.53, issue.14, pp.1211-1218, 2009. ,
DOI : 10.1016/j.jacc.2008.12.038
C Chemokine Fractalkine in Pulmonary Arterial Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.165, issue.10, pp.1419-1425, 2002. ,
DOI : 10.1164/rccm.2106007
Chemokine RANTES in Severe Pulmonary Arterial Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.165, issue.4, pp.534-539, 2002. ,
DOI : 10.1164/ajrccm.165.4.2012112
Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension., American Journal of Respiratory and Critical Care Medicine, vol.151, issue.5, pp.1628-1631, 1995. ,
DOI : 10.1164/ajrccm.151.5.7735624
Plasma Brain Natriuretic Peptide as a Prognostic Indicator in Patients With Primary Pulmonary Hypertension, Circulation, vol.102, issue.8, pp.865-870, 2000. ,
DOI : 10.1161/01.CIR.102.8.865
Serum Uric Acid Levels Correlate with the Severity and the Mortality of Primary Pulmonary Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.160, issue.2, pp.487-492, 1999. ,
DOI : 10.1164/ajrccm.160.2.9812078
Osteopontin in Patients With Idiopathic Pulmonary Hypertension, Chest, vol.139, issue.5, pp.1010-1017, 2011. ,
DOI : 10.1378/chest.10-1146
Biomarkers in pulmonary hypertension, European Respiratory Journal, vol.32, issue.2, pp.503-512, 2008. ,
DOI : 10.1183/09031936.00160307
The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension, European Respiratory Journal, vol.39, issue.3, pp.589-596, 2012. ,
DOI : 10.1183/09031936.00092311
Biomarkers in pulmonary hypertension, European Respiratory Journal, vol.32, issue.2, pp.503-512, 2008. ,
DOI : 10.1183/09031936.00160307
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension, Journal of the American College of Cardiology, vol.40, issue.4, pp.780-788, 2002. ,
DOI : 10.1016/S0735-1097(02)02012-0
URL : https://doi.org/10.1016/s0735-1097(02)02012-0
Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL), Circulation, vol.122, issue.2, pp.164-172, 2010. ,
DOI : 10.1161/CIRCULATIONAHA.109.898122
Do Changes of 6-Minute Walk Distance Predict Clinical Events in Patients With Pulmonary Arterial Hypertension?, Journal of the American College of Cardiology, vol.60, issue.13, pp.1192-1201, 2012. ,
DOI : 10.1016/j.jacc.2012.01.083
Validation of 6-Minute Walk Distance as a Surrogate End Point in Pulmonary Arterial Hypertension Trials, Circulation, vol.126, issue.3, pp.349-356, 2012. ,
DOI : 10.1161/CIRCULATIONAHA.112.105890
Baseline and Follow-up 6-Min Walk Distance and Brain Natriuretic Peptide Predict 2-Year Mortality in Pulmonary Arterial Hypertension, Chest, vol.143, issue.2, pp.315-323, 2013. ,
DOI : 10.1378/chest.12-0270
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694187/pdf
Updated Treatment Algorithm of Pulmonary Arterial Hypertension, Journal of the American College of Cardiology, vol.62, issue.25, pp.60-72, 2013. ,
DOI : 10.1016/j.jacc.2013.10.031
PATHOBIOLOGY OF PULMONARY HYPERTENSION, Clinics in Chest Medicine, vol.22, issue.3, pp.451-458, 2001. ,
DOI : 10.1016/S0272-5231(05)70283-5
Plasma coagulation profiles in patients with severe primary pulmonary hypertension, European Respiratory Journal, vol.12, issue.6, pp.1446-1449, 1998. ,
DOI : 10.1183/09031936.98.12061446
URL : http://erj.ersjournals.com/content/erj/12/6/1446.full.pdf
Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension., American Journal of Respiratory and Critical Care Medicine, vol.150, issue.4, pp.929-933, 1994. ,
DOI : 10.1164/ajrccm.150.4.7921465
Anticoagulation and Survival in Pulmonary Arterial HypertensionClinical Perspective, Circulation, vol.129, issue.1, pp.57-65, 2014. ,
DOI : 10.1161/CIRCULATIONAHA.113.004526
URL : http://circ.ahajournals.org/content/circulationaha/129/1/57.full.pdf
Anticoagulant therapy does not influence long-term outcomes in patients with pulmonary arterial hypertension (PAH): insights from the randomised controlled SERAPHIN trial of macitentan, Eur Heart J, vol.35, p.10, 0194. ,
Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)CLINICAL PERSPECTIVE, Circulation, vol.132, issue.25, p.2464, 2014. ,
DOI : 10.1161/CIRCULATIONAHA.115.018435
Optimal diuretic therapy for heart failure, The American Journal of Medicine, vol.111, issue.7, p.577, 2001. ,
DOI : 10.1016/S0002-9343(01)00915-9
The Short-term Effects of Digoxin in Patients With Right Ventricular Dysfunction From Pulmonary Hypertension, Chest, vol.114, issue.3, pp.787-792, 1998. ,
DOI : 10.1378/chest.114.3.787
Iron deficiency is common in idiopathic pulmonary arterial hypertension, European Respiratory Journal, vol.37, issue.6, pp.1386-1391, 2011. ,
DOI : 10.1183/09031936.00100510
URL : http://erj.ersjournals.com/content/erj/37/6/1386.full.pdf
Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension, Rheumatology, vol.53, issue.2, pp.285-292, 2014. ,
DOI : 10.1093/rheumatology/ket331
Blood Viscosity and its Relationship to Iron Deficiency, Symptoms, and Exercise Capacity in Adults With Cyanotic Congenital Heart Disease, Journal of the American College of Cardiology, vol.48, issue.2, pp.356-365, 2006. ,
DOI : 10.1016/j.jacc.2006.03.040
URL : https://doi.org/10.1016/j.jacc.2006.03.040
Iron Deficiency and Raised Hepcidin in Idiopathic Pulmonary Arterial Hypertension, Journal of the American College of Cardiology, vol.58, issue.3, pp.300-309, 2011. ,
DOI : 10.1016/j.jacc.2011.02.057
URL : https://doi.org/10.1016/j.jacc.2011.02.057
Iron deficiency is associated with adverse outcome in Eisenmenger patients, European Heart Journal, vol.32, issue.22, pp.2790-2799, 2011. ,
DOI : 10.1093/eurheartj/ehr130
Pregnancy outcomes in pulmonary arterial hypertension in the modern management era, European Respiratory Journal, vol.40, issue.4, pp.881-885, 2012. ,
DOI : 10.1183/09031936.00141211
Pregnancy Outcome in Patients With Pulmonary Arterial Hypertension Receiving Prostacyclin Therapy, Obstetrics & Gynecology, vol.106, issue.5, Part 2, pp.1206-1210, 2005. ,
DOI : 10.1097/01.AOG.0000164074.64137.f1
Severe Pulmonary Hypertension during Pregnancy, Anesthesiology, vol.102, issue.6, pp.1133-1137, 2005. ,
DOI : 10.1097/00000542-200506000-00012
Pregnancy and contraception in heart disease and pulmonary arterial hypertension, Journal of Family Planning and Reproductive Health Care, vol.32, issue.2, pp.75-81, 2006. ,
DOI : 10.1783/147118906776276486
URL : http://jfprhc.bmj.com/content/familyplanning/32/2/75.full.pdf
Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease, Am Rev Respir Dis, vol.131, pp.493-498, 1985. ,
Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey, European Respiratory Journal, vol.41, issue.6, pp.1302-1307, 2013. ,
DOI : 10.1183/09031936.00089212
Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease, Am Rev Respir Dis, vol.131, pp.493-498, 1985. ,
mutation: Figure 1???, European Respiratory Journal, vol.39, issue.6, pp.1534-1535, 2012. ,
DOI : 10.1183/09031936.00185011
Understanding the impact of pulmonary arterial hypertension on patients' and carers' lives, European Respiratory Review, vol.22, issue.130, pp.535-542, 2013. ,
DOI : 10.1183/09059180.00005713
Outils de dialogue pour les aidants 197 Rapport de l'OMS-Europe, publié en 1996, Therapeutic Patient Education ? Continuing Education Programmes for Health Care Providers in the field of Chronic Disease, traduit en français en, 1998. ,